Squarepoint’s Royalty Pharma RPRX Stock Holding History

Squarepoint’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,500	Closed	-$212K	–	5424
2024 Q3	$212K	Buy	+7,500	New	+$208K	﹤0.01%	3653

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Squarepoint's RPRX Position: Q1 2026 in Review

Squarepoint reduced its Royalty Pharma (RPRX) stake by 13% in Q1 2026, selling an estimated $9.05M and leaving 1,349,516 shares worth $64.7M. The position accounts for 0.08% of the portfolio, ranked #259.

Squarepoint first reported a position in RPRX in Q2 2020 and has held it in 22 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Squarepoint held 1,349,516 shares of Royalty Pharma worth $64.7M as of Q1 2026.
Squarepoint sold 206,725 Royalty Pharma shares in Q1 2026, an estimated $9.05M.
Royalty Pharma made up 0.08% of Squarepoint's portfolio in Q1 2026, its #259 holding.
Squarepoint first reported a position in Royalty Pharma in Q2 2020 and has held it in 22 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.